Magnetoencephalography (MEG) is a non-invasive technique used to measure and record the brain’s electrical activity. It uses highly sensitive superconducting detectors to measure and monitor the magnetic fields produced by the electrical currents of the brain. This technology is used to measure electrical brain activity with accuracy and precision without invasively inserting any electrical probes or wires into the brain. It is non-invasive and therefore, carries no risk of trauma or infection. MEG can be used to identify electrical sources and pathways in the brain. This enables physicians to diagnose neurological and psychiatric disorders such as Alzheimer's, epilepsy, and autism. MEG can also help scientists further understand brain mechanisms and functions associated with perception, motor control, language processing, learning, and memory. Recent advances in MEG have given scientists better tools to study brain function. The newest technology uses sophisticated computer-based signal processing algorithms to capture and analyze the brain’s activity with high accuracy. This provides researchers with a powerful way to observe the activity within different areas of the brain. MEG can also be used to monitor the effects of drugs and treatments on the brain and can be used to optimize and personalize patient care. For instance, recently, a study showed that MEG was helpful in determining the most effective medication for treating epilepsy. In conclusion, MEG is a revolutionary technology that has enabled scientists and medical professionals to study and observe the brain’s electrical activity accurately and precisely.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States